Philips announced that it will introduce a next-generation monitoring solution for at-risk patients in low-acuity hospital settings, such as the general ward.

GE Healthcare announced two large systems integrators (SIs) and seven leading-edge independent software vendors (ISVs) are planning to move their digital solutions to the new GE Health Cloud. Designed exclusively for the healthcare industry and resting on the shoulders of GE’s Predix platform, the GE Health Cloud will ultimately connect more than 2 million imaging machines worldwide, including 500,000 GE Healthcare devices.

Nexstim Plc announced that the Data Safety Monitoring Board (DSMB), an independent committee of experts monitoring the Phase III stroke therapy NICHE trial, has reviewed the interim analysis data. The DSMB notes that the pre-specified stopping criteria for futility have been met and therefore the trial will not meet its primary endpoint. However, the DSMB further notes that they acknowledge that the treatments and enrolment have been completed. They recommend that the study team and subjects remain blinded and data collection be completed.

Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards Sapien XT transcatheter heart valve for pulmonic valve replacement procedures.

Cardiac stem cells could be an effective treatment for a common but difficult-to-treat type of heart failure, a new study from the Cedars-Sinai Heart Institute shows.

Stratasys Ltd., the 3-D printing and additive manufacturing solutions company, will be featured at the Healthcare Information and Management Systems Society (HIMSS) 2016 conference and exhibition. This is the first time 3-D printing will be a part of the annual conference, which will take place Feb. 29 – Mar. 4 in Las Vegas.

JC Medical Inc. announced that it has successfully completed an implantation of its J-Valve bioprosthesis using the Ausper transapical delivery device in Vancouver, Canada. The J-Valve Ausper system represents the next generation of transcatheter aortic valve implantation (TAVI) systems and has been previously used in more than 100 patients in China. This operation is the first implantation of the J-Valve Ausper system outside of China.

For the first time in the United States, a clinical trial is underway that’s evaluating a device designed to treat diastolic heart failure. The first patient enrolled in the randomized, blinded study is being treated at The Ohio State University Wexner Medical Center.

February 29, 2016 — APN Health LLC announced it received U.S. Food and Drug Administration (FDA) clearance to market Navik 3D, an advanced cardiac mapping system that reduces the cost and complexity of electrophysiology procedures.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now